581 related articles for article (PubMed ID: 16489684)
1. Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.
Ji GZ; Wang XH; Miao L; Liu Z; Zhang P; Zhang FM; Yang JB
World J Gastroenterol; 2006 Jan; 12(4):644-8. PubMed ID: 16489684
[TBL] [Abstract][Full Text] [Related]
2. Role of Smad proteins in the regulation of NF-kappaB by TGF-beta in colon cancer cells.
Grau AM; Datta PK; Zi J; Halder SK; Beauchamp RD
Cell Signal; 2006 Jul; 18(7):1041-50. PubMed ID: 16288847
[TBL] [Abstract][Full Text] [Related]
3. Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-beta.
Park YN; Chae KJ; Oh BK; Choi J; Choi KS; Park C
Hepatogastroenterology; 2004; 51(56):396-400. PubMed ID: 15086168
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma.
Abou-Shady M; Baer HU; Friess H; Berberat P; Zimmermann A; Graber H; Gold LI; Korc M; Büchler MW
Am J Surg; 1999 Mar; 177(3):209-15. PubMed ID: 10219856
[TBL] [Abstract][Full Text] [Related]
5. [Detection of the expression of Smad4, transforming growth factor beta(1) and beta receptor II proteins in paraffin-embedded human pancreatic cancer tissues].
Gu L; Chen J; Liu T; Li L; Lu Z; Luo Y
Zhonghua Bing Li Xue Za Zhi; 2001 Dec; 30(6):439-42. PubMed ID: 11866987
[TBL] [Abstract][Full Text] [Related]
6. Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling.
Torbenson M; Marinopoulos S; Dang DT; Choti M; Ashfaq R; Maitra A; Boitnott J; Wilentz RE
Hum Pathol; 2002 Sep; 33(9):871-6. PubMed ID: 12378510
[TBL] [Abstract][Full Text] [Related]
7. Role of transforming growth factor-beta signaling pathway in pathogenesis of benign biliary stricture.
Geng ZM; Zheng JB; Zhang XX; Tao J; Wang L
World J Gastroenterol; 2008 Aug; 14(31):4949-54. PubMed ID: 18756605
[TBL] [Abstract][Full Text] [Related]
8. Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis.
Lu Y; Wu LQ; Li CS; Wang SG; Han B
Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):174-8. PubMed ID: 18397854
[TBL] [Abstract][Full Text] [Related]
9. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation.
Arsura M; Panta GR; Bilyeu JD; Cavin LG; Sovak MA; Oliver AA; Factor V; Heuchel R; Mercurio F; Thorgeirsson SS; Sonenshein GE
Oncogene; 2003 Jan; 22(3):412-25. PubMed ID: 12545162
[TBL] [Abstract][Full Text] [Related]
10. Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Lange D; Persson U; Wollina U; ten Dijke P; Castelli E; Heldin CH; Funa K
Int J Oncol; 1999 Jun; 14(6):1049-56. PubMed ID: 10339656
[TBL] [Abstract][Full Text] [Related]
11. TGF-β and NF-κB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers.
Freudlsperger C; Bian Y; Contag Wise S; Burnett J; Coupar J; Yang X; Chen Z; Van Waes C
Oncogene; 2013 Mar; 32(12):1549-59. PubMed ID: 22641218
[TBL] [Abstract][Full Text] [Related]
12. Lack of responsiveness to TGF-beta1 in a thyroid carcinoma cell line with functional type I and type II TGF-beta receptors and Smad proteins, suggests a novel mechanism for TGF-beta insensitivity in carcinoma cells.
Heldin NE; Bergström D; Hermansson A; Bergenstråhle A; Nakao A; Westermark B; ten Dijke P
Mol Cell Endocrinol; 1999 Jul; 153(1-2):79-90. PubMed ID: 10459856
[TBL] [Abstract][Full Text] [Related]
13. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
14. [Correlations of TGF-betaRII, Smad4 and Smad7 expression to clinicopathologic characteristics and prognosis of gastric cancer].
Lu B; Zhou YN; Li Q; Wu ZQ; Zhang ZY; Ji R; Guo QH; Liu W
Ai Zheng; 2009 May; 28(5):538-42. PubMed ID: 19624886
[TBL] [Abstract][Full Text] [Related]
15. Effects of Chinese traditional compound, JinSanE, on expression of TGF-beta1 and TGF-beta1 type II receptor mRNA, Smad3 and Smad7 on experimental hepatic fibrosis in vivo.
Song SL; Gong ZJ; Zhang QR; Huang TX
World J Gastroenterol; 2005 Apr; 11(15):2269-76. PubMed ID: 15818738
[TBL] [Abstract][Full Text] [Related]
16. Role of TGF-beta1, its receptor TGFbetaRII, and Smad proteins in the progression of colorectal cancer.
Gulubova M; Manolova I; Ananiev J; Julianov A; Yovchev Y; Peeva K
Int J Colorectal Dis; 2010 May; 25(5):591-9. PubMed ID: 20165854
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-β signaling pathway in Marfan's syndrome: a preliminary histopathological study.
Yuan SM; Ma HH; Zhang RS; Jing H
Vasa; 2011 Sep; 40(5):369-74. PubMed ID: 21948779
[TBL] [Abstract][Full Text] [Related]
18. TGF-β signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cells.
Mu X; Lin S; Yang J; Chen C; Chen Y; Herzig MC; Washburn K; Halff GA; Walter CA; Sun B; Sun LZ
PLoS One; 2013; 8(5):e63436. PubMed ID: 23704908
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor.
Persson U; Souchelnytskyi S; Franzén P; Miyazono K; ten Dijke P; Heldin CH
J Biol Chem; 1997 Aug; 272(34):21187-94. PubMed ID: 9261125
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin plus norcantharidin alter the expression of TGF-β1/Smads signaling pathway in hepatocellular carcinoma.
Li KY; Shi CX; Huang JZ; Tang KL
Bratisl Lek Listy; 2017; 118(2):85-88. PubMed ID: 28814088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
